ZA201608844B - Succinate dehydrogenase inhibitors (sdhi's) - Google Patents

Succinate dehydrogenase inhibitors (sdhi's)

Info

Publication number
ZA201608844B
ZA201608844B ZA2016/08844A ZA201608844A ZA201608844B ZA 201608844 B ZA201608844 B ZA 201608844B ZA 2016/08844 A ZA2016/08844 A ZA 2016/08844A ZA 201608844 A ZA201608844 A ZA 201608844A ZA 201608844 B ZA201608844 B ZA 201608844B
Authority
ZA
South Africa
Prior art keywords
sdhi
succinate dehydrogenase
dehydrogenase inhibitors
inhibitors
succinate
Prior art date
Application number
ZA2016/08844A
Other languages
English (en)
Inventor
Chouchani Edward
Krieg Thomas
Saeb-Parsy Kourosh
Patrick Murphy Michael
Work Lorraine
Frezza Christian
Original Assignee
Medical Res Council
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Council, Cambridge Entpr Ltd filed Critical Medical Res Council
Publication of ZA201608844B publication Critical patent/ZA201608844B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2016/08844A 2014-07-03 2016-12-21 Succinate dehydrogenase inhibitors (sdhi's) ZA201608844B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1411937.4A GB201411937D0 (en) 2014-07-03 2014-07-03 Succinate dehydrogenase inhibitors (SDH's)
PCT/GB2015/051949 WO2016001686A1 (en) 2014-07-03 2015-07-03 SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's)

Publications (1)

Publication Number Publication Date
ZA201608844B true ZA201608844B (en) 2019-04-24

Family

ID=51410633

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/08844A ZA201608844B (en) 2014-07-03 2016-12-21 Succinate dehydrogenase inhibitors (sdhi's)

Country Status (10)

Country Link
US (1) US10603298B2 (enExample)
EP (1) EP3164126B1 (enExample)
JP (1) JP2017519020A (enExample)
CN (1) CN106714793B (enExample)
AU (1) AU2015282424A1 (enExample)
CA (1) CA2953709A1 (enExample)
GB (1) GB201411937D0 (enExample)
SG (1) SG11201610588UA (enExample)
WO (1) WO2016001686A1 (enExample)
ZA (1) ZA201608844B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148550A1 (en) * 2017-02-10 2018-08-16 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
WO2019139831A1 (en) * 2018-01-10 2019-07-18 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate
WO2020041470A1 (en) * 2018-08-21 2020-02-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods of metabolic regulation of mitochondria for treating neural injury and neurological disorders using dsh inhibitors
CN109793760B (zh) * 2019-02-13 2022-07-19 中国人民解放军总医院 琥珀酸弧菌属在预防或治疗高原病药物中的用途
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury
US11813239B2 (en) * 2020-02-18 2023-11-14 Wisconsin Alumni Research Foundation Compositions and methods for improving cardiac structure and/or function
GB202108594D0 (en) 2021-06-16 2021-07-28 Cambridge Entpr Ltd Treatment or prevention of ischaemia reperfusion injury
WO2025125766A1 (en) 2023-12-12 2025-06-19 Cambridge Enterprise Limited Treatment or prevention of ischaemia reperfusion injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032403B1 (en) 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US20070173545A1 (en) * 2003-11-07 2007-07-26 Ajay Verma Activation of hypoxia-inducible gene expression
ES2391662T3 (es) 2006-09-28 2012-11-28 Medical Research Council Donadores de óxido nítrico de tionitrílo de trifenilfosfonio
WO2011156181A1 (en) * 2010-06-08 2011-12-15 Montefiore Medical Center Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins
WO2013152193A2 (en) * 2012-04-04 2013-10-10 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
US20140128352A1 (en) * 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production
WO2014179187A1 (en) * 2013-04-29 2014-11-06 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities

Also Published As

Publication number Publication date
WO2016001686A1 (en) 2016-01-07
JP2017519020A (ja) 2017-07-13
US20170135977A1 (en) 2017-05-18
US10603298B2 (en) 2020-03-31
CA2953709A1 (en) 2016-01-07
CN106714793A (zh) 2017-05-24
CN106714793B (zh) 2020-12-01
AU2015282424A1 (en) 2017-01-12
EP3164126A1 (en) 2017-05-10
EP3164126B1 (en) 2021-02-24
GB201411937D0 (en) 2014-08-20
SG11201610588UA (en) 2017-01-27

Similar Documents

Publication Publication Date Title
AU2015342774B2 (en) EZH2 inhibitors and uses thereof
EP3148589B8 (en) Stable cannabinoid formulations
EP3179856A4 (en) Transdermal cannabinoid formulations
EP3177288A4 (en) Prmt5 inhibitors and uses thereof
EP3160477A4 (en) Prmt5 inhibitors and uses thereof
EP3193600A4 (en) Smyd inhibitors
EP3160466A4 (en) Prmt5 inhibitors and uses thereof
EP3193608A4 (en) Carm1 inhibitors and uses thereof
IL246785A0 (en) Benzimidazole-2-amines as midh1 inhibitors
EP3116503A4 (en) Hptp-beta inhibitors
EP3193611A4 (en) Mk2 inhibitors and uses thereof
ZA201608844B (en) Succinate dehydrogenase inhibitors (sdhi's)
EP3096754A4 (en) Metallo-beta-lactamase inhibitors
EP3159340A4 (en) New bruton's tyrosine kinase inhibitor
EP3185787A4 (en) Reformable guidewire tip
EP3187181A4 (en) Emulsion composition
EP3256450A4 (en) Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
EP3193939A4 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
EP3197885A4 (en) Heterocyclic compounds and use thereof
EP3148971A4 (en) Deubiquitinase inhibitors
EP3224794A4 (en) Dynamic user experience workflow
EP3097084A4 (en) New kallikrein 7 inhibitors
GB201409487D0 (en) User location tracking
EP3095439A4 (en) Emulsion composition for skin
EP3161490A4 (en) COMPOSITIONS AND METHODS FOR DETECTING HUMAN PEGIVIRUS 2 (HPgV-2)